Mixed aortic valve disease: Midterm outcome and predictors of adverse events

Alexander Egbe, Joseph T. Poterucha, Carole A. Warnes

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Aims: The aim of this article is to determine freedomfrom adverse events (AE) defined as symptoms, aortic valve replacement (AVR), or death in the mixed aortic valve disease (MAVD) population. Methods and results: We reviewed patients with moderate/severe MAVD followed at Mayo Clinic from 1994-2013. Only asymptomatic patients with normal ejection fraction and trileaflet aortic valve were included. Cox proportional-hazard models and Kaplan-Meier method were used. We identified 213 patients with moderate/severe MAVD; mean age was 69 years (±11) and 67% were males. An AE endpoint was reached in 172 patients, and 69% of these AEs occurred in moderate MAVD (peak velocity of 3-3.9 m/s). Mean follow-up was 10.1±3 years, and mean time to AE was 2.9±2.1 years. A mechanical prosthesis was implanted in 71/151 (47%), and 54/151 (36%) had concomitant coronary artery bypass grafting and/or aorta replacement during AVR. Early surgical mortality was 0.7%. Freedom from AE endpoint was 42% [confidence interval (CI) 39-45%] and 30% (CI 27-33%) at 3 and 5 years, respectively. Predictors of AE were peak aortic velocity [hazard ratio (HR) 2.73; CI 1.97-2.84, P < 0.0001] for every 1 m/s difference and having severe stenosis or severe regurgitation at presentation (HR 2.58; CI 2.01-4.44, P = 0.001). Conclusion: Moderate MAVD had high rate of AEs comparable to severe isolated aortic stenosis and should be followed as such. Patients with severe MAVD should be evaluated at least every 6 months because half of them will become symptomatic and require AVR within 1 year.

Original languageEnglish (US)
Pages (from-to)2671-2678
Number of pages8
JournalEuropean Heart Journal
Volume37
Issue number34
DOIs
StatePublished - Jan 1 2016

Fingerprint

Aortic Diseases
Aortic Valve
Confidence Intervals
Aortic Valve Stenosis
Proportional Hazards Models
Coronary Artery Bypass
Prostheses and Implants
Aorta
Pathologic Constriction

Keywords

  • Aortic regurgitation
  • Aortic stenosis
  • Aortic valve replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mixed aortic valve disease : Midterm outcome and predictors of adverse events. / Egbe, Alexander; Poterucha, Joseph T.; Warnes, Carole A.

In: European Heart Journal, Vol. 37, No. 34, 01.01.2016, p. 2671-2678.

Research output: Contribution to journalArticle

Egbe, Alexander ; Poterucha, Joseph T. ; Warnes, Carole A. / Mixed aortic valve disease : Midterm outcome and predictors of adverse events. In: European Heart Journal. 2016 ; Vol. 37, No. 34. pp. 2671-2678.
@article{094be5c14a3e4a7d95a7ea944b954910,
title = "Mixed aortic valve disease: Midterm outcome and predictors of adverse events",
abstract = "Aims: The aim of this article is to determine freedomfrom adverse events (AE) defined as symptoms, aortic valve replacement (AVR), or death in the mixed aortic valve disease (MAVD) population. Methods and results: We reviewed patients with moderate/severe MAVD followed at Mayo Clinic from 1994-2013. Only asymptomatic patients with normal ejection fraction and trileaflet aortic valve were included. Cox proportional-hazard models and Kaplan-Meier method were used. We identified 213 patients with moderate/severe MAVD; mean age was 69 years (±11) and 67{\%} were males. An AE endpoint was reached in 172 patients, and 69{\%} of these AEs occurred in moderate MAVD (peak velocity of 3-3.9 m/s). Mean follow-up was 10.1±3 years, and mean time to AE was 2.9±2.1 years. A mechanical prosthesis was implanted in 71/151 (47{\%}), and 54/151 (36{\%}) had concomitant coronary artery bypass grafting and/or aorta replacement during AVR. Early surgical mortality was 0.7{\%}. Freedom from AE endpoint was 42{\%} [confidence interval (CI) 39-45{\%}] and 30{\%} (CI 27-33{\%}) at 3 and 5 years, respectively. Predictors of AE were peak aortic velocity [hazard ratio (HR) 2.73; CI 1.97-2.84, P < 0.0001] for every 1 m/s difference and having severe stenosis or severe regurgitation at presentation (HR 2.58; CI 2.01-4.44, P = 0.001). Conclusion: Moderate MAVD had high rate of AEs comparable to severe isolated aortic stenosis and should be followed as such. Patients with severe MAVD should be evaluated at least every 6 months because half of them will become symptomatic and require AVR within 1 year.",
keywords = "Aortic regurgitation, Aortic stenosis, Aortic valve replacement",
author = "Alexander Egbe and Poterucha, {Joseph T.} and Warnes, {Carole A.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1093/eurheartj/ehw079",
language = "English (US)",
volume = "37",
pages = "2671--2678",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "34",

}

TY - JOUR

T1 - Mixed aortic valve disease

T2 - Midterm outcome and predictors of adverse events

AU - Egbe, Alexander

AU - Poterucha, Joseph T.

AU - Warnes, Carole A.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Aims: The aim of this article is to determine freedomfrom adverse events (AE) defined as symptoms, aortic valve replacement (AVR), or death in the mixed aortic valve disease (MAVD) population. Methods and results: We reviewed patients with moderate/severe MAVD followed at Mayo Clinic from 1994-2013. Only asymptomatic patients with normal ejection fraction and trileaflet aortic valve were included. Cox proportional-hazard models and Kaplan-Meier method were used. We identified 213 patients with moderate/severe MAVD; mean age was 69 years (±11) and 67% were males. An AE endpoint was reached in 172 patients, and 69% of these AEs occurred in moderate MAVD (peak velocity of 3-3.9 m/s). Mean follow-up was 10.1±3 years, and mean time to AE was 2.9±2.1 years. A mechanical prosthesis was implanted in 71/151 (47%), and 54/151 (36%) had concomitant coronary artery bypass grafting and/or aorta replacement during AVR. Early surgical mortality was 0.7%. Freedom from AE endpoint was 42% [confidence interval (CI) 39-45%] and 30% (CI 27-33%) at 3 and 5 years, respectively. Predictors of AE were peak aortic velocity [hazard ratio (HR) 2.73; CI 1.97-2.84, P < 0.0001] for every 1 m/s difference and having severe stenosis or severe regurgitation at presentation (HR 2.58; CI 2.01-4.44, P = 0.001). Conclusion: Moderate MAVD had high rate of AEs comparable to severe isolated aortic stenosis and should be followed as such. Patients with severe MAVD should be evaluated at least every 6 months because half of them will become symptomatic and require AVR within 1 year.

AB - Aims: The aim of this article is to determine freedomfrom adverse events (AE) defined as symptoms, aortic valve replacement (AVR), or death in the mixed aortic valve disease (MAVD) population. Methods and results: We reviewed patients with moderate/severe MAVD followed at Mayo Clinic from 1994-2013. Only asymptomatic patients with normal ejection fraction and trileaflet aortic valve were included. Cox proportional-hazard models and Kaplan-Meier method were used. We identified 213 patients with moderate/severe MAVD; mean age was 69 years (±11) and 67% were males. An AE endpoint was reached in 172 patients, and 69% of these AEs occurred in moderate MAVD (peak velocity of 3-3.9 m/s). Mean follow-up was 10.1±3 years, and mean time to AE was 2.9±2.1 years. A mechanical prosthesis was implanted in 71/151 (47%), and 54/151 (36%) had concomitant coronary artery bypass grafting and/or aorta replacement during AVR. Early surgical mortality was 0.7%. Freedom from AE endpoint was 42% [confidence interval (CI) 39-45%] and 30% (CI 27-33%) at 3 and 5 years, respectively. Predictors of AE were peak aortic velocity [hazard ratio (HR) 2.73; CI 1.97-2.84, P < 0.0001] for every 1 m/s difference and having severe stenosis or severe regurgitation at presentation (HR 2.58; CI 2.01-4.44, P = 0.001). Conclusion: Moderate MAVD had high rate of AEs comparable to severe isolated aortic stenosis and should be followed as such. Patients with severe MAVD should be evaluated at least every 6 months because half of them will become symptomatic and require AVR within 1 year.

KW - Aortic regurgitation

KW - Aortic stenosis

KW - Aortic valve replacement

UR - http://www.scopus.com/inward/record.url?scp=84992402763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992402763&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehw079

DO - 10.1093/eurheartj/ehw079

M3 - Article

C2 - 26994155

AN - SCOPUS:84992402763

VL - 37

SP - 2671

EP - 2678

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 34

ER -